<乌鸦传媒>Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
<乌鸦传媒>FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
<乌鸦传媒>FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
<乌鸦传媒>Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
<乌鸦传媒>Atorvastatin Tied to Cardioprotection for Lymphoma Patients on Anthracyclines STOP-CA deemed "an impactful study that will lead to more prescription of statins in patients." Mar 04, 2023
<乌鸦传媒>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<乌鸦传媒>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
<乌鸦传媒>Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
<乌鸦传媒>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<乌鸦传媒>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<乌鸦传媒>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma European trial is "practice-changing as of today," says U.S. expert Dec 13, 2022
<乌鸦传媒>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody Most complete responses lasted 24 months or longer after limited-duration glofitamab Dec 13, 2022
<乌鸦传媒>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging Data from St. Jude cohort show higher rates of neurocognitive impairment Dec 13, 2022
<乌鸦传媒>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<乌鸦传媒>ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
<乌鸦传媒>'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<乌鸦传媒>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<乌鸦传媒>Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
<乌鸦传媒>What Caused Man's Saddle-Nose Deformity Years After Lymphoma Dx? Rare diagnosis points to need for thorough workup in patients with severe nasal congestion Aug 01, 2022
<乌鸦传媒>Breast Implant-Related Lymphoma More Common Than Reported Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
<乌鸦传媒>Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
<乌鸦传媒>Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
<乌鸦传媒>Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<乌鸦传媒>FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
<乌鸦传媒>Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
<乌鸦传媒>Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
<乌鸦传媒>Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
<乌鸦传媒>Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
<乌鸦传媒>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<乌鸦传媒>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<乌鸦传媒>Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
<乌鸦传媒>Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
<乌鸦传媒>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<乌鸦传媒>FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<乌鸦传媒>Growing Controversy Over 'Skinny' Labeling for Generic Drugs What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
<乌鸦传媒>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<乌鸦传媒>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
